Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2012, 156(2):171-179 | DOI: 10.5507/bp.2011.048

The value of 18F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy

Miroslav Mysliveceka, Cestmir Neoralb, Radek Vrbab, Katherine Vomackovab, Jan Cincibuchc, Radim Formaneka, Pavel Korandaa, Jana Zapletalovad
a Department of Nuclear Medicine, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
b Department of Surgery I, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc
c Department of Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc
d Department of Biophysics, Faculty of Medicine and Dentistry, Palacky University Olomouc

Aim: To evaluate the ability of hybrid 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) to predict histopathological response and overall survival (OS) after preoperative neoadjuvant chemoradiotherapy (CRT) in patients with the esophageal carcinoma.

Methods: 73 patients with locally advanced esophageal carcinoma were included in the study. All were treated with CRT and 34 subsequently underwent surgical resection of the esophagus. 18F-FDG PET/CT was carried out prior to (PET/ CT1) and 6 weeks after (PET/CT2) completion of the CRT.

Results: PET/CT2-determined complete metabolic response (CMR) was achieved in 6 (17.6%) out of 34 operated patients, the metabolic response was incomplete (NCMR) in 28 (82.4%) patients. A histopathological complete response (CR) to CRT was discovered in 7 patients (20.6%). The median OS in operated patients was 17.1 months, 95% CI:12.9-23.3 months. In a group of 39 non-operated patients, CMR after neoadjuvant CRT was achieved in 12 patients (30.8%), while NCMR was found in 28 (82.4%). The median OS was 13.5 months in this group, 95% CI: 4.4-22.7 months.

Conclusion: No statistically significant correlation was found between the 18F-FDG metabolic response after the neoadjuvant CRT and histopathological response. Presently, the contribution of 18F-FDG PET/CT as a marker of the potential result of CRT cannot be considered definite. Another study with a larger sample of patients and standardized algorithms for the examining protocols would be necessary for reaching definitive conclusions.

Keywords: esophageal carcinoma, neoadjuvant chemoradiotherapy, 18F-FDG PET/CT, tumor response

Received: June 7, 2011; Accepted: September 5, 2011; Prepublished online: November 1, 2011; Published: June 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago IEEE ISO690 MLA NLM Turabian Vancouver
Myslivecek, M., Neoral, C., Vrba, R., Vomackova, K., Cincibuch, J., Formanek, R., Koranda, P., & Zapletalova, J. (2012). The value of 18F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy. Biomedical papers, 156(2), 171-179. doi: 10.5507/bp.2011.048
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Parkin DM. International variation. Oncogene 2004;23:6329-40. Go to original source... Go to PubMed...
    2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30. Go to original source... Go to PubMed...
    3. Reis L, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK, eds. SEER Cancer Statistic Review, 1973-97. Bethesda, MD: National Cancer Institute, 2000.
    4. Berrino F, Capocaccia R, Esteve J, Gatta G, Hakulinen T, Micheli A, Sant M., Verdacchia A, eds. Survival of Cancer Patients in Europe: the EUROCARE2 Study. IARC Scientific Publications No.51, Lyon: IARC, 1999.
    5. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-52. Go to original source... Go to PubMed...
    6. Krause BJ, Herrmann K, Wieder H, zum Buschenfelde CM. 18F-FDG PET and 18F-FDG PET/CT for Assessing Response to Therapy in Esophageal Cancer. J Nucl Med 2009;50:89S-96S. Go to original source... Go to PubMed...
    7. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-34. Go to original source... Go to PubMed...
    8. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J. Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 2007;8:226-34. Go to original source... Go to PubMed...
    9. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20. Go to original source... Go to PubMed...
    10. Walsh TN, Noonan M, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996;335:462-7. Go to original source... Go to PubMed...
    11. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M, Sahmoud T. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 1997;337:161-7. Go to original source... Go to PubMed...
    12. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patiens with locoregional esophageal carcinoma. J Clin Oncol 2001;19:305-13. Go to original source... Go to PubMed...
    13. Lee JL, Park SI, Kim SB, Jung HY, Lee GH, Kim JH, Song HY, Cho KJ, Kim WK, Lee JS, Kim SH, Min YI. A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 2004;15:947-54. Go to original source... Go to PubMed...
    14. Berger AC, Farma J, Scott WJ, Freedman G, Weiner L, Cheng JD, Wang H, Goldberg M. Complete response to neoadjuvant chemoradiotherapy in esophageal carcinoma is associated with significantly improved survival. J Clin Oncol 2005;23:4330-7. Go to original source... Go to PubMed...
    15. Kim SB, Park SI, Kim JH. A phase II trial of preoperative one cycle of induction chemotherapy [capecitabine(CAP), CDDP] followed by concurrent chemoradiation (CRT) in patients with resectable esophageal cancer. J Clin Oncol 2005;23:4063[abstract]. Go to original source... Go to PubMed...
    16. Heath EI, Burtness BA, Heitmiller RF, Salem R, Kleinberg L, Knisely JP, Yang SC, Talamini MA, Kaufman HS, Canto MI, Topazian M, Wu TT, Olukayode K, Forastiere AA. Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. J Clin Oncol 2000;18:868-76. Go to original source... Go to PubMed...
    17. Ponsner MC, Forastiere AA, Minsky BD. Cancer of the esophagus. In: Devuta TV, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 7th ed. Philadelphia (PA): Lippincot Williams and Wilkins 2005, p.861-909.
    18. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C, Wilke H. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005;23:2310-7. Go to original source... Go to PubMed...
    19. Kim MK, Ryu JS, Kim SB, Ahn JH, Kim SY, Park SI, Kim YH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Cho KJ, Kim JH. Value of complete metabolic response by 18F-fluorodeoxyglucosepositron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy. Eur J Cancer 2007;43:1385-91. Go to original source... Go to PubMed...
    20. Jones DR, Parker LA, Detterberk FC, Egan TM. Inadequacy of computed tomography in assessing patients with esophageal carcinoma after induction chemoradiotherapy. Cancer 1999;85:1026-32. Go to original source... Go to PubMed...
    21. Beseth BD, Bedford R, Isacoff WH, Holmes EC, Cameron RB. Endoscopic ultrasound does not accurately assess pathologic stage of esophageal cancer after neoadjuvant chemoradiotherapy. Am Surg 2000;66:827-31. Go to original source... Go to PubMed...
    22. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoit T, Foidart-Willems J. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996;23:1641-74. Go to original source... Go to PubMed...
    23. Swisher SG, Maish M, Erasmus JJ, Correa AM, Ajani JA, Bresalier R, Komaki R, Macapinlac H, Munden RF, Putnam JB, Rice D, Smythe WR, Vaporciyan AA, Walsh GL, Wu TT, Roth JA. Utility of PET, CT and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg 2004;78:1152-60. Go to original source... Go to PubMed...
    24. Brücher BL, Weber W, Bauer M, Fink U, Avril N, Stein HJ, Werner M, Zimmerman F, Siewert JR, Schwaiger M. Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 2001;233:300-9. Go to original source... Go to PubMed...
    25. Flamen P, Van Cutsem E, Lerut A, Cambier JP, Haustermans K, Bormans G, De Leyn P, Van Raemdonck D, De Wever W, Ectors N, Maes A, Mortelmans L. Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 2002;13:361-8. Go to original source... Go to PubMed...
    26. Levine EA, Farmer MR, Clark P, Mishra G, Ho C, Geisinger KR, Melin SA, Lovato J, Oaks T, Blackstock AW. Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg 2006;243:472-8. Go to original source... Go to PubMed...
    27. Song SY, Kim JH, Ryu JS, Lee GH, Kim SB, Park SI, Song HY, Cho KJ, Ahn SD, Lee SW, Shin SS, Choi EK. FDG-PET in the prediction of pathologic response after neoadjuvant chemoradiotherapy in locally advanced, resectable esophageal cancer. Int J Radiat Oncol Biol Phys 2005;63:1053-9 . Go to original source... Go to PubMed...
    28. Mc Ateer D, Wallis F, Couper GW, Norton M, Welch A, Bruce D, Park K, Nicolson M, Gilbert FJ, Sharp P. Evaluation of 18F-FDG positron emission tomography in gastric and oesophageal cancer. Br J Radiol 1999;72:529. Go to original source... Go to PubMed...
    29. Flanagan FL, Dehdashti F, Siegel BA, Trask DD, Sundaresan SR, Patterson GA, Cooper JD. Staging of esophageal cancer with 18F-fluorodeogyglucose positron emission tomography. Am J Roenthenol 1997;168:417-24. Go to original source... Go to PubMed...
    30. Cook G, Taylor H, Mason R, Rankin S, Fogelman I. A comparison of 18FDG PET and CT in the staging of oesophageal carcinoma. J Nucl Med 1997;38(Suppl):247. Abstract 1043.
    31. Block MI, Patterson GA, Sundaresan RS, Bailey MS, Flanagan FL, Dehdashti F, Siegel BA, Cooper JD. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thoracic Surg 1997;64:776-7. Go to original source... Go to PubMed...
    32. Luketich JD, Friedman DM, Weigel TL, Methan MA, Keenan RJ, Townsend DW, Meltzer CC. Evaluation of distant metastases in oesophageal cancer: 100 consecutive positron emission tomography scans. Ann Thoracic Surg 1999;68:1133-6. Go to PubMed...
    33. Flamen P, Lerut A, Van Cutsen E. Utility of positron emission tomography for staging of patiens with potentially operable esophageal carcinoma. J Clin Oncol 2000;18:3202-10. Go to original source... Go to PubMed...
    34. Kneist W, Schreckenberger M, Bartenstein P, Menzel C, Oberholzer K, Junginger T. Prospective evaluation of positron emission tomography in the preoperative staging of esophageal carcinoma. Arch Surg 2004;139:1043-9. Go to original source... Go to PubMed...
    35. Couper GW, McAteer D, Wallis F, Norton M, Welch A, Nicolson M, Park KG. The detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg 1998;85:1403-6. Go to original source... Go to PubMed...
    36. Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschläger G, Busch R, Siewert JR, Schwaiger M, Fink U. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2002;19:3058-65. Go to original source... Go to PubMed...
    37. Kato H, Kuwano H, Nakajima M, Miyazaki T, Yoshikawa M, Masuda N, Fukuchi M, Manda R, Tsukada K, Oriuchi N, Endo K. Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 2002;184:279-83. Go to original source... Go to PubMed...
    38. Brink I, Hentschel M, Bley TA, Walch A, Mix M, Kleimaier M, Moser E, Imdahl A. Effects of neoadjuvant radio-chemotherapy on 18F-FDG PET in esophageal carcinoma. EJSO 2004;30:544-50. Go to original source... Go to PubMed...
    39. Downey RJ, Akhurst T, Ilson D, Ginsberg R, Bains MS, Gonen M, Koong H, Gollub M, Minsky BD, Zakowski M, Turnbull A, Larson SM, Rusch V.khurst T, Ilson D. Whole body 18FDG-PET and response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol 2003;21:428-32. Go to original source... Go to PubMed...
    40. Smithers BM, Couper GC, Thomas JM, Wong D, Gotley DC, Martin I, Harvey JA, Thomson DB, Walpole ET, Watts N, Burmeister BH. Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus. Deseases of the Esophagus 2008;21:151-8. Go to original source... Go to PubMed...
    41. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA, Eloubeidi MA. The accuracy of endoscopic ultrasonography with fine-needle asporation, integrated positron emission tomography with computed tomography, and computed tomography in restaging patients with esophageal cancer after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg 2005;129:1241-2. Go to original source... Go to PubMed...
    42. Port JL, Lee PC, Korst RJ, Liss Y, Meherally D, Christos P, Mazumdar M, Altorki NK. Positron emission tomographic scanning predicts survival after induction chemotherapy for esophageal carcinoma. Ann Thorac Surg 2007;84:393-400. Go to original source... Go to PubMed...
    43. Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert JR. Metabolic imaging predicts response, survival and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol 2006;24:4692-8. Go to original source... Go to PubMed...
    44. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, Roussel A, Jacob JH, Segol P, Samama G. Pathologic assessment of tumour regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathologiocal correlations. Cancer 1994;73:2580-686. Go to original source... Go to PubMed...
    45. Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Böttcher K, Siewert JR, Höfler H. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521-30. Go to original source... Go to PubMed...
    46. Lordick F, Ott K, Krause BJ, Weber WA, Becker K, Stein HJ, Lorenzen S, Schuster T, Wieder H, Herrmann K, Bredenkamp R, Höfler H, Fink U, Peschel C, Schwaiger M, Siewert JR. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the esopgagogastric junction: the MUNICON phase II trial. Lancet Oncol 2007;8:797-805. Go to original source... Go to PubMed...
    47. Higuchi I, Yasuda T, Yano M, Doki Y, Miyata H, Tatsumi M, Fukunaga H, Takiguchi S, Fujiwara Y, Hatazawa J, Monden M. Lack of fludeoxygflucose F18 uptake on posttreatment positron emission tomography as a signifiant predictor of survival after subsequens surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma. J Thorac Cardiovasc Surg 2008;136:205-12. Go to original source... Go to PubMed...

    Return to the content